However, as with most solid tumors, only a minority of ESCC patients (20-30%) benefit from anti-PD-1 therapy2–4, highlighting that the immune system can be exploited for clinical benefits in ESCC. This evidence concerns the gene PDCD1 and esophageal squamous cell carcinoma.